Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

NCT07749365 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma
PCNSL (Primary CNS Lymphoma)

Interventions

DRUG: hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab

Sponsor

The First Affiliated Hospital of Xiamen University